Editas upgraded at Wells Fargo as Australia approves gene editing trial
Wells Fargo upgraded its investment outlook for Editas (EDIT) based on the Australian gene editing clinical approval.
Considering Wells Fargo's bullish investment outlook and its position between the 20-day low support line ($2.42) and the high-point resistance line ($3.14), given that the Moving Average Align is in an unaligned state, we considered entering via a split approach near the support line.
Based on the current price of $2.83, I will take profit if it reaches the high-point resistance level of $3.14, and I will exit if it breaches the 20-day low support level of $2.42.
The RSI(14) shows neutral momentum at 51.2, while the moving average is in an abnormal state. Trading volume is at 0.70 times the 20-day average, and the recent 7-day volatility has reached +9.6%.
I entered the trade based on Wells Fargo's rating upgrade and the stock's position between the June 20 support level ($2.42) and resistance level ($3.14). However, the actual result was a -13.5% return, reaching the stop-loss level and resulting in a FAILED rating. In hindsight, I regret not being sufficiently cautious of the fact that technical indicators at the time—such as an RSI(14) of 51.2, non-aligned moving averages, and low trading volume (0.70x)—failed to support strong upward momentum, and that the number of thematic news items was on a falling trend.
Based on the failure of this trade, going forward, even if there is positive news, we will more conservatively filter out entries when moving averages are not in a proper bullish alignment or when trading volume falls short of the average (e.g., around 0.70x). In particular, when the trend in the number of news items for a theme is on the decline, we will reflect actionable adjustments by applying stricter stop-loss criteria to prepare for downside risk, even if technical indicators are neutral.